³X«È Åwªï±z!   ·|­ûµn¤J


 ¦^¥D­¶  ¡÷    ­«¤j¯S®í¯e¯f°Ï  ¡÷  ¥»½g¥DÃD¡G²Ä1 «¬¿}§¿¯f



 
¡i¤W¤@½g¡j[ ¦p¦ó¦­´Áµo²{µÇª¢ ] ¡i¤U¤@½g¡j[ ¦p¦ó«Ø¥ß®a±Ú¯f¥v¬ö¿ý ]

    [¤À¨É]    ²Ä1 «¬¿}§¿¯f

    ada   µoªí©ó 2008/6/17 10:51:02



²Ä1 «¬¿}§¿¯fªºªvÀø²{ªp»P¥¼¨Óªº®i±æ ªL¤fªø©°¨àµ£Âå°|¨àµ£¤º¤Àªc·s³¯¥NÁ¬ì- ùºÖªQÂå®v ²Ä1 «¬¿}§¿¯f¬O¦]¬°¯ØÅ¦¯Ø®q²Ó­M³Q¦ÛÅé§K¬Ì©Î¤£ª¾­ì¦]¯}Ãa¦ÓµLªk¤Àªc¯Ø®q¯À¡F³o»P²Ä2 «¬¿}§¿¯f¬O¦]¬°¯Ø®q¯À±Ó·P©Ê¤£¦n¡]ªý§Ü¡^¦X¨Ö¬Û¹ïªº¯Ø®q¯À¯Ê¥F¬O¤£¦Pªº¡A¥iÂǥѤfªAÃĪ«§ïµ½¯Ø®q¯À±Ó·P©Ê©Î¨ë¿E¯Ø®q²Ó­M¤Àªc§ó¦hªº¯Ø®q¯À¨Ó¸Ñ¨M¡C©Ò¥H¡A²Ä1 «¬¿}§¿¯f»Ý­n¯Ø®q¯À¨Ó¸É¥R¡A¦p¦ó¸É¥R¡H¥»¤å±N¤¶²Ð·í«eª`®gªº¯Ø®q¯À¡B§l¤J©Ê¯Ø®q¯ÀªºÁ{§É¸ÕÅçµ²ªG¡B¯ØÅ¦²¾´Ó¤Î¯Ø®q²Ó­M²¾´Ó¡C¥t¥~´ú¦å¿}¤]¤@ª½¬O¿}§¿¯f±w©Ò®£Äߪº¡A³Ìªñ´ú¦å¿}¤â¿ö³°Äò¦³¨â´Ú¤W¥«¡A¤j¤j´î»´¤F¿}§¿¯f±wªºÀ£¤O¡A©Ò¥H¥»¤å¤]·|¤©¥H¤¶²Ð¡C ½Í¨ì¯Ø®q¯Àªº¸É¥R´N¥ý»Ý­nª¾¹D¥¿±`¤Hªº¯Ø®q¯À¤Àªc¤è¦¡¡A¥i¥H¤À¬°¨âºØ ¤è¦¡¡G 1. «ùÄò©Ê°ò¦©Ê¯Ø®q¯À¤Àªc¡A¥i¥H§í¨î¨xŦ¸²µå¿}ªº¥Í¦¨»P¨­Å鸣³¡¤Î¨ä¥L²Õ´¸²µå¿}ªº°ò¦¨Ï¥Î¡C 2. À\«á¯Ø®q¯Àªº¤Àªc¼W¥[¡A¥i¥H¼W¥[À\«á¦]®ø¤Æ©Ò§l¦¬¿}¤Àªº¸²µå¿}¨Ï¥Î»PÀx¦s¡A¶i¦Ó±±¨î¦å¿}ªº¤W¤É¡C ¥¿±`¤H24 ¤p®Éªº¦å¿}¿@«×»P¯Ø®q¯Àªº¤Àªc ¯Ø®q¯À­n¦p¦ó¥h¼Ò¥é¥¿±`¤Hªº¯Ø®q¯À¤Àªc¤è¦¡¡H¤@¯ë¨Ó»¡¡AÀ\«á¦å¿}ªº±±¨î¡A»Ý­n¨CÀ\«e¾a³t®Ä«¬©Îµu®Ä«¬ªº¯Ø®q¯À¨Ó§@¥Î¡F°ò¦©Ê¯Ø®q¯ÀªºªvÀø«h¾a¤@¤Ñ¤@¦¸¡]insulin glargine¡^©Î¨â¦¸¡]insulin detemir ©Îultartard¡^ªº¤¤©Îªø®Ä¯Ø®q¯À¨ÓÀ°¦£¡C ±µµÛ¡A§A­n¤F¸Ñ¥«­±¤Wªº¯Ø®q¯ÀºØÃþ¡A¨Ì§@¥Î®É¶¡¥i¤À¬°¥H¤U¤­Ãþ¡G 1. ³t®Ä«¬¡A¥~Æ[²Mº«¡A°Ó«~¦pHumalog¡BNovorapid¡Binsulin glulisine¡A¬ù5-15¤ÀÄÁ«á¶}©l§@¥Î¡A¤ñ¤@¯ëµu®Ä¯Ø®q¯À§@¥Î§Ö¡A©Ò¥H¸¹ºÙ¥i°¨¤W¥´°¨¤W¦Y¡A§@¥Î³Ì°ª®p¬°0.5-1.5 ¤p®É¡A¦³®Ä§@¥Î®É¶¡¬°3-5 ¤p®É¡A¤ñ¸û¤£·|»P¤¤®Ä«¬¯Ø®q¯À§@¥Î®É¶¡­«Å|¡C 2. µu®Ä«¬¡A¥~Æ[²Mº«¡A°Ó«~¦pActrapid¡BVelosulin¡BHumulin R µ¥RI »s¾¯¡A¬ù1/2-1 ¤p®É«á¶}©l§@¥Î¡A§@¥Î³Ì°ª®p¬°2-3 ¤p®É¡A¦³®Ä§@¥Î®É¶¡¬°5-8¤p®É¡C 3. ¤¤®Ä«¬¡A¥~Æ[¥Õ¦â²V¿B¡A°Ó«~¦pProstaphane¡BInsulatard¡BMonotard¡BHumulinN µ¥NPH ©ÎLente »s¾¯¡A¬ù2-4 ¤p®É«á¶}©l§@¥Î¡A§@¥Î³Ì°ª®p¬°4-10 ¤p®É¡A¦³®Ä§@¥Î®É¶¡¬°10-18 ¤p®É¡C 4. ªø®Ä«¬¡A°Ó«~¦pUltratard¡BLantus¡Binsulin detemir µ¥¡A¬ù4 ¤p®É«á¶}©l§@¥Î¡A§@¥Î³Ì°ª®p¬°4-12 ¤p®É¡A¦³®Ä§@¥Î®É¶¡¬°18-30 ¤p®É¡C 5. ²V¦X«¬¯Ø®q¯À¡A¦pHumulin 70/30 (70% insulin portamine 30% regular)¡BMixtard HM 70/30(70% insulin portamine , 30% regular)¡BNovoMix (70% insulinaspart portamine , 30% insulin aspart)¡Aµu®Ä»P¤¤®Ä©Î³t®Ä»P¤¤®Ä¯Ø®q¯À¥H©T©w¤ñ¨Ò²V¦X¡A§@¥Î¦³Âù°ª®p¡C ¯Ø®q¯Àªºª`®g¦¸¼Æ¡A¬O³\¦h¤pªB¤Í³ÌÃö¤ßªº¡C¨ä¹ê¡Aª`®g¯Ø®q¯Àªº¥Øªº¬O§â¦å¿}±±¨î¦n¡Cµ§ªÌ»{¬°¦Ü¤Ö¤@¤Ñ¨â¦¸¥H¤W¡A¤~¯à§â¦å¿}±±¨î¦n¡C¬ü°ê»P¥[®³¤jDCCT ¬ã¨s¤¤¿n·¥ªvÀø²Õ¬O¤@¤Ñª`®g¤T¦¸¥H¤W¯Ø®q¯À¤ÎÅç¦å¿}¥|¦¸¥H¤W¡A¶Ç²ÎªvÀø²Õ¬O¤@¤Ñª`®g1-2 ¦¸¯Ø®q¯À¤ÎÅç¦å¿}©Î§¿¿}¡A¥i¨£Åç¦å¿}¶V¦h¦¸¡B¯Ø®q¯À¶V¦h¦¸¡A¦å¿}±±¨î¶V¦n¡C ¨ä¤¤¥H¤@¤Ñ¥|¦¸¯Ø®q¯Àª`®g¬O³Ì²Å¦X¥Í²z»Ý¨D¤]¬O³Ì¦nªº¡A¦]¬°¤¤©Îªø®Ä¯Ø®q¯À´£¨Ñ¤F°ò¦©Êªº¯Ø®q¯À»Ý­n¡AÀ\«eµu©Î³t®Ä¯Ø®q¯À¥i¥H¨Ì§A¶i­¹®É¶¡¤ÎÀ\ÂI¤j¤p¨Ó½Õ¾ã§A¦Û¤vªºµu©Î³t®Ä¯Ø®q¯Àªº¾¯¶q¡A«D±`¼u©Ê¡F³o¨ä¤¤¤S¥Hªø®Ä¯Ø®q¯Àglargine ·f°t³t®Ä¯Ø®q¯À³Ì¨Î¡C¦ý¬O¡A¨C­Ó¤H¦]¬°¦~ÄÖ¡BÅé½è¡B¤u§@¡B¶¼­¹¡B¥Í¬¡²ßºD¡Bª`®gªº®£Äßµ¥¥i¥H»P§AªºÂå®v°Q½×³Ì¾A¦X§Aªº¯Ø®q¯Àª`®g¦¸¼Æ¤Î¤è¦¡¡A¥[¤W¶¼­¹±±¨î¡B¹B°Êµ¥°È¥²§â¦å¿}±±¨î¦n¡A¦]¬°¿}§¿¯f¥»¨­¤£®£©Æ¡A¦Ó¬Oªø´ÁºC©Êªº°ª¦å¿}·|¾É­P²´·ú¡BµÇŦ¡B¯«¸g¡B¤ßŦ¤Î¦åºÞµ¥¾¹©x¨ü·l¡B¥\¯à¤£¨}¬Æ¦Ü°IºÜ¡C ¯Ø®q¯À®Aµ©¤]¬O¤@­Ó«D±`²Å¦X¥Í²z»Ý¨D¡A¥¦´£¨Ñ¤F«ùÄò©Ê¥Ö¤U¯Ø®q¯Àª`®g¡]continuous subcutaneous insulin infusion¡A²ºÙCSII¡^¡A¤@¶}©l±N¥Ø«e¤@¤Ñªº¯Ø®q¯ÀÁ`¾¯¶q¥ý´î25%«á¡A¤@¥b¾¯¶q¤À¦¨24 ¤p®Éºâ¥X¡u³æ¦ì/¤p®É¡v§@¬°¨C¤p®É°ò¦¾¯¶q¡A¥t¥~¤@¥b¾¯¶q¤À¦¨3 ¥÷¡]¬ù17%¡^¥H§@¦­À\¡B¤ÈÀ\¡B±ßÀ\¥[±j¥Î¡C³oºØ«ùÄò©Ê¥Ö¤U¯Ø®q¯Àª`®gªºÀuÂI¡A¬O¹ï©ó¶Ç²Î¥Ö¤Uª`®g¤´±±¨î¤£¦n¡A®e©ö¤Ï´_§C¦å¿}ªº¤H¥i§ïµ½¦å¿}±±¨î(¤×¨ä·f°t³t®Ä¯Ø®q¯À)¡A¨Ã´£¨Ñ¤ñ¸û¼u©Ê¥B²Å¦X¥Í²zªº¥Í¬¡¤è¦¡¡A§Y·Ç³Æ¥ÎÀ\®É¡A¦Aª`®g¥[±j¯Ø®q¯À¡A¦ý¬O¨Ï¥Î¯Ø®q¯À®Aµ©ªº¯f¤H¦³¨ä±ø¥ó¡G¤@¤Ñ¦Ü¤ÖÅç4 ¦¸¦å¿}¡A¦³³d¥ô·P¥B¤ß´¼¥¿±`¡A¹ï­¹ª«¤­¤jÃþ¡B¥N´«¤Î¥÷¶q«Ü¤F¸Ñ¡AÄ@·N»PÂåÅ@¤H­û¦X§@¡C¥¦ªº³Ì¤j¯ÊÂI¬O«D±`©ù¶Q(¤@¥x18 ¸U)¡A¨Ï ¥Î¯Ø®q¯À®Aµ©ªº¯f¤H¡A¨C¤T¤Ñ´«ÀY¥Ö°w¤Î¿é²GºÞ(600 ¤¸)¤@¦¸¡A©Ò¥H¤U°w³¡¦ìªº²M¼ä»P½Ã¥Í«Ü­«­n¡AÁ×§K·P¬V¡C¥t¥~¡A­Y¯Ø®q¯À®Aµ©Ãa¤F¡A¥²¶·»°§Ö§ï¦¨¶Ç²Î¥Ö¤Uª`®g¡A§_«h®e©ö¦]¬°¯Ø®q¯À¯Ê¥F¦Ó଻Ĥ¤¬r¡Cµ§ªÌ¹ï¥¦ªº¦L¶H«Ü¦n¡A¦]¬°µ§ªÌ´X­Ó¤ë«e¹J¨ì¤@¦ì¤Ï´_§C¦å¿}ªº¤H§ï¥Î¤F¯Ø®q¯À®Aµ©·f°t³t®Ä¯Ø®q¯À¡A¤j¤j§ïµ½§C¦å¿}¦¸¼Æ¥B¿}¤Æ¦å¦â¯À¦Ü4.7¡A¦ý¬O¥¦¹ê¦b¤Ó¶Q¤F¡C ´ú¦å¿}¤â¿ö¥Ø«e¦b°ê¥~¦³¨âºØ¡A»ù¿ú«D±`©ù¶Q¡A¤À§O¬°GlucoWatch G2 Biographer ¤ÎPendra¡A³£¬O¦å¿}ºÊ´ú¸Ë¸m¡A´N¹³¤â¿ö¤@¼ËÀ¹¦b¤âµÃ¤W¡A¤£»Ý­n¨Ï¥Î±Ä¦å°w¨Ó¨ú¦å¡CGlucoWatch ³o­Ó¸Ë¸m¬O¨C¤Q¤ÀÄÁ¸g¥Ñ¥Ö½§°µ«D«I¤J¦¡ªº¦å¿}¶q´ú¡A¬ù¥i«ùÄò¤Q¤T­Ó¤p®É¡A³o¨ÇŪ­È¥i¥Î¨Ó°lÂܦå¿}ªºÅܤƥH¸É±Ä¦å¶q´ú¤§¤£¨¬¡A¦ý¨Ã¤£¯à¨ú¥N±Ä¦å¶q´úªº¤è¦¡¡AGlucoWatch ¥i¥Î¦b¦¨¦~¤H¤Î¤C·³¥H¤Wªº«Äµ£¡A¥¦¥²¶·¸g¥ÑÂå®v³B¤è«ü¥Ü¤~¥i¨Ï¥Îªº¸Ë¸m¡FGlucoWatch »Ý­n¨C12 ¤p®É§ó´«·PÀ³¹Ô¡A¸g¹L¢±­Ó¤p®Éªº·x¾÷¡A¯f±w¥ý±Ä¦å¨Ó°µ®Õ¥¿ªº°Ê§@¡A®Õ¥¿¤§«á¡A¸Ë¸m´N¶}©lºÊ´ú¦å¿}­È¡A¹q¦À²£¥Íªº¤p¹q¬y±NÅé²G¸g¹L¥Ö½§©â¥X¤§«á¶i¤J³o­Ó¸Ë¸m¡AµM«á¹q·¥«K¶q´úÅé²G¤¤ªº¦å¿}­È¡C®Ú¾ÚÁ{§É¬ã¨sÅã¥Ü¡AGlucoWatch ©Ò´ú±oªº¦å¿}¼Æ¾Ú»P¶Ç²Î¤ã°w¨ú¦åªºÀË´ú¤èªk¬Û¸û¡A¦³³Ì¦h25% ªº®É¶¡©µ¿ð¡AÁö¤£¼vÅT¹ïµ²ªGªº¤ÀªR¡A¦ý­Y¦b§Ö³tÅܤƪº±¡ªp¡]¦p§C¦å¿}¯gª¬¡^µo¥Í¡A¤´«ØÄ³¨Ï¥Î¤ã°w¨ú¦å©Ò´ú±oªºµ²ªG¨Ó¹ï·Ó¡C¦Ü©óPendra ´ú¦å¿}¤â¿ö¡A«h¬O§Q¥Î¹qªý¥úÃоǭì²z¨Ó·PÀ³¥Ö¤U²Õ´¤Î¦å²Gªº¿}¤À¿@«×¡A¥¦¥i¥H¨C¤ÀÄÁ³sÄò©Ê´ú¶q¦å¿}¿@«×¡A¥¦¤£»Ý­n¹³GlucoWatch §ó´«·PÀ³¹Ô¡A¹q¸ôªOª½±µ¦b¿ö©³¡A©Ò¥H¬Ù¤F·PÀ³¹Ô¡]¬ù$5-10/pc¡A2 pc/¤Ñ¡^ªº©ù¶Q¶O¥Î¡A¦Ó¥B¦Ü¥Ø«e¬°¤î¨ÃµL®É¶¡©µ¿ð²{¶Hªº³ø§i¡A¦ý¬O¤´»Ý­n©w´Á¹ï·Ó¤ã°w¨ú¦å©Ò´ú±oªºµ²ªG¡CGlucoWatch ¤ÎPendra ³£¦³¤º«Ø¦¡ªºÄµ³ø¾¹¥i¥H³]©w­Y¦å¿}­È°ª©ó©Î§C©ó³]©w½d³ò¡A«h¦Û°Êĵ³ø¡C ¯ØÅ¦»P¯Ø®q²¾´Ó ¯ØÅ¦»P¯Ø®q²¾´Óªº¥Øªº¤£»Ýª`®g¯Ø®q¯Àºû«ù¦å¿}¥¿±`,Á×§KºC©Ê¨Öµo¯g,§ïµ½¥Í¬¡«~½è¡C¯ØÅ¦²¾´Ó¯f¨Ò¦Ü2000 ¦~¦@¦³14,000 ¨Ò,¤â³N¤j³¡¥÷»PµÇŦ¦P®É²¾´Ó,³N«á1 ¦~¤Î3 ¦~¤£»Ý¨Ì¿à¯Ø®q¯ÀªvÀøªº¦¨¥\²v¦U¬ù80%¤Î70%,¦¨¥\ªº¯f¨Ò¯«¸g¯fÅÜ»P¥Í¬¡«~½èÀò±o§ïµ½. ¯ØÅ¦²¾´Ó¯f¤Hªº¿ï¾Ü(1)¦X¨ÖµÇ°IºÜ»Ý¶i¦æµÇŦ²¾´Ó,¯Ø®q¯ÀªvÀøµo¥Í°ÝÃD,(2)¥¼¦X¨ÖµÇ°IºÜ,¯Ø®q¯ÀªvÀø¦³ÄY­«ªº°ÝÃD¡A¸g±`µo¥Í«æ©Ê¨Öµo¯g¡C¯ØÅ¦²¾´Ó°ê¥~¦h¥Î¦b¤¤¦~¤H¨­¤W¡A«Ü¤Ö¥Î¦b10 ´X·³«C¤Ö¦~¨­¤W¡C ¯Ø®q²¾´Ó«h¬O±N¯Ø®q²Ó­M¦Û¯ØÅ¦¤ÀÂ÷¤Î¯Â¤Æ«á¡A¸g¥Ñªù¯ß´Ó¤J¨xŦ¡C±q1893¦Ü2000 ¦~¦@¦³¬ù493 ¦W±wªÌ±µ¨ü¯Ø®q²¾´Ó¡A¨ä¤@¦~¤£»Ý¨Ì¿à¯Ø®q¯Àªº¦¨¥\²v¬°8%¡C¤£¹L¡A³Ìªñ¥[®³¤jAlberta ¤j¾Ç³ø§i33 ¦ì¿}§¿¯f¯f¤H¦b³N«á¤@¦~ªº¦¨¥\²v°ª¹F80%¡C¥Ø«eªL¤fªø©°²ø®mîÚÂå®v¹Î¶¤¥¿§V¤O¬ã¡A¥H¦­¤é±N¯Ø®q²¾´ÓÀ³¥Î©óÁ{§É¨Óªv¡¿}§¿¯f¯f¤H¡C¦Ó¯Ø®q²¾´Ó¤]»Ý­nªA¥Î§K¬Ì§í¨î¾¯¡A©Ò¥H¤´­nª`·N¤W­zªº¦X¨Ö¯g¡C ¿}§¿¯fªvÀø¥¼¨Óªº®i±æ §l¤J©Ê¯Ø®q¯À ¦Û±q¯Ø®q¯À±qª¯¯ØÅ¦µÑ¨ú¥X¨ÓªvÀø¦Ü²{¦b°ò¦]¦X¦¨¡A³\¦h¯f±w³£¥Ñ°J§Æ±æ¯Ø®q¯À¯à±qª`®g§ï¦¨¨ä¥L¤è¦¡¡A´î»´¥L­Ìª`®gªº®£Äß¡F³o´X¦~¨Ó¡A¦³¦n´X®aÃļtµÛ¤âµo®i§l¤J©Ê¯Ø®q¯À¡A¨ä¤¤¥Ñ½÷·ç¡]Pfizer¡^©MÁɿյá¦w¸U¯S¡]Sanofi-Aventis¡^Ãļt¦X§@µo®iªº§l¤J©Ê¯Ø®q¯ÀExubera ¤w¦V¬ü°ê­¹«~ÃĪ«ºÞ²z§½FDA ´£¤W¥«¥Ó½Ð¥Î©ó²Ä1 «¬¤Î²Ä2 «¬¿}§¿¯fªº¦¨¤H¨Ï¥Î¡A¥¦¥Ø«e¤]¦b¼Ú¬wÂåÃĵû¦ô§½(EuropeanMedicines Evaluation Agency,EMEA)µû¦ô¤¤¡CExubera ¬O¤@ºØ°®¦¡ªº¯Ø®q¯À¯»¥½¡A¸g¥Ñ¯S§O³]­pªºNektar Advanced Pulmonary Technology §l¤J¸Ë¸mÅýÃĪ«¶i¤JªÍ³¡ ¦Ó³Q§l¦¬¡AÃĪ«§@¥Î®É¶¡¤j¬ù»Pµu®Ä¯Ø®q¯À®É¶¡¬Û·í¡A©Ò¥H­Y¨Ï¥Î©óªvÀø¿}§¿¯f«h»Ý­n·Ó¤TÀ\«e¬I¤©·f°tªø®Ä¯Ø®q¯Àglargine¡]²Ä1 «¬¿}§¿¯f¡^©Î¤fªA­°¦å¿}ÃĪ«¡]²Ä2 «¬¿}§¿¯f¡^¡C¦¹ÃĪºÁ{§É¸ÕÅçÁnºÙ¤w¦³¶W¹L3500 ¤H¨Ï¥Î¹L¡A¦³¨Ç¤w¶W¹L7 ¦~¡A¦Ü©ó¬O§_·|¹ïªÍ¥\¯à³y¦¨¶Ë®`ªº°Æ§@¥Î¾ÚºÙ«Ü¤p¡A¦³¿à¬ü°ê­¹«~ÃĪ«ºÞ²z§½FDA ¤Î¼Ú·ùEMEA ªº§âÃö¡C ¥Ø«e¡A¦³Ãļt¥¿¦bÁ{§É¸ÕÅç¯Ø®q¯À¶K¥¬¨Ó·í°ò¦©Ê¯Ø®q¯À¡A¦ý®ÄªG¥¿¦bÃҹꤤ¡A­Y¯à·f°t§l¤J«¬¯Ø®q¯À¡A´N¯uªº§K°w¤F¡CÁ`¤§¡A¬ì¾Ç®a¥¿§V¤O¬ãµo¯à´î»´¯f±wªºµh­W¡A¦ý­Y¨S¦³¨}¦nªº¶¼­¹±±¨î¤Î³W«ßªº¹B°Ê¡A¦å¿}¤´µM±±¨î¤£·|¦n¡A©Ò¦³¬ì¾Ç®aªº§V¤O¤]³£ªPµM¡C °]¹Îªk¤H¿}§¿¯fÃöÃh°òª÷·|2005 ¦~¡u¿}§¿¯f®a±Ú¡v





   µoªí¥DÃD ¦^ÂÐ¥DÃD

¥Ø«e©|µL¦^ÂÐ...

¤ý®v¤÷±M·~Àð¾À¤Á¤ÕÆp¤Õ¤Þ¤Õ¤uµ{ªA°È
¥x¥_Æp¤Õ¤Á³Î ¤T­«Æp¤Õ¤Á³Î
ªO¾ôÆp¤Õ¤Á³Î ·s²øÆp¤Õ¤Á³Î
Àð¾ÀÆp¤Õ¤Á³Î,Àð­±¤Þ¤ÕÆp¤Õ,¦aªOÆp¤Õ¤Á³Î

[±ÀÂ˵û»ù¦n©±] - 4C§Ö­×³sÂêªù¥« ±M·~ºû­×¶R½æ-µ§¹q+¤â¾÷+¹q¸£+Iphone+Ipad
·s¥_¦Á¤î©± (02) 7751-9182
·s¥_¥«¦Á¤î°ÏºÖ¼w¤@¸ô86«Ñ22¸¹
·s¥_ªO¾ô©± (02) 8257-3990
·s¥_¥«ªO¾ô°Ï¥|ºû¸ô137«Ñ10¸¹
®ç¶é¤j·Ë©± (03) 387-4353
®ç¶é¥«¤j·Ë°Ï¤¤µØ¸ô210¸¹
¥x¤¤¥«°Ï©± (04) 2201-1289
¥x¤¤¥«¤¤°Ï¥x¤¤¸ô140¸¹


   ¥xÆWÂåÀø½×¾Â ¦^³»ºÝ
¦Û¾AÀ³ºô­¶½d¥»


³sµ²Àu¨}¸ê°T¤J¤fºô ¥»¯¸¤J³ò½Ã¥Í¸p95¦~«×Àu¨}°·±d¸ê°Tºô¯¸ ¥xÆWÂåÀøºô © 2006 Taiwan Inc. All Rights Reserved.

*«ØÄ³IE5.0¥H¤W¤§ÂsÄý¾¹ ¸ÑªR1024*768 ¥H¹F³Ì¨ÎÂsÄý®ÄªG* ¥þ¯¸¨Ì¤º®e¤À¯Å³W©w³B²z